A quarter of patients fail to stomach survodutide.
With Boehringer locked in, the Danish biotech wants more partners for monotherapies, combos and more.
Obesity is biopharma’s hottest ticket, and Boehringer Ingelheim wants a seat at the show.
Hopes are high that a buyer will emerge, but the fast-moving downfall of a big name in biopharma banking is not over yet.
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.